Featured Abstracts and Author Insights

---

ACG 2021 Newsworthy Abstracts Highlight Cutting-Edge Clinical GI Science

This page is a gateway to explore the clinical GI science featured at the 2021 ACG Annual Scientific Meeting. Here you will find award-winning abstracts, commentary and perspective from select authors of newsworthy findings, and tips to navigate the array of clinical research being presented at ACG 2021 by investigators working to advance digestive health and improve patient care.

The authors of ACG’s Newsworthy Abstracts, selected by the ACG Public Relations Committee, provide additional perspective on their findings and explain what the clinical science means for patients. Following the links below, reporters can explore these Newsworthy Abstracts and author insights and connect with these researchers for media stories. To review all ACG Press Releases, visit Media Statements.

• Final Program Book for ACG 2021 Annual Scientific Meeting
  • The Final Program Book contains information for the Plenary Session oral papers, some of the major science being presented at the meeting.
• ACG 2021 Conference Platform
  • Tip: the online Conference Platform will help you access the full text of the abstracts.
• Award-Winning Abstracts
  • ACG’s Presidential Posters are highly meritorious projects selected by the Educational Affairs Committee, and the College recognizes excellent clinical research by organ-system category as well as research by fellows-in-training.
• Newsworthy Abstracts
  • Explore some of the papers and presentations selected by reviewers from ACG’s Educational Affairs and Public Relations Committees, a distinguished group of experts who suggested papers and posters with innovative, newsworthy, and/or significant findings.

Nominated by the ACG Public Relations Committee, this group of abstracts features scientific findings that are innovative, newsworthy for the lay reader, relevant to those who suffer from common GI problems, and which represent a significant advancement in the diagnosis and treatment of GI diseases. The Committee aims to identify novel and thought-provoking abstracts which reinforce key public health messages, such as emerging research on GI manifestations of COVID-19, the importance of colorectal cancer screening (particularly for minority and at-risk populations), or which feature common GI problems in a new way.

• Oral 1 Mean Adenomas Per Colonoscopy Is Inversely Associated With Post Colonoscopy Colorectal Cancers: Data From the New Hampshire Colonoscopy Registry Validating This Quality Measure; Joseph C. Anderson, MD, MHCDS, FACG
• Oral 2 Prospective Randomized Trial Comparing Endocuff-Assisted Colonoscopy vs G-EYE Balloon-Assisted Colonoscopy: A Multicenter Study; Seth A. Gross, MD, FACG
• Oral 3 Humoral Immune Response After Completion of COVID-19 Vaccine Series Among Patients With IBD; Kimberly N. Weaver, MD
• Oral 5 Secondary Prophylaxis of Gastric Variceal Bleeding: A Systematic Review and Network Meta-Analysis; Karim T. Osman, MD
• Oral 7 Rapid Prediction of H. pylori Antibiotic Resistance Using Next Generation Sequencing of Stool Samples Compared to Gastric Biopsies; Steven Moss, MD, FACG
• Oral 8 Optimizing Endoscopy Procedure Documentation Improves Guideline Adherent Care in Upper Gastrointestinal Bleeding; Timothy Yen, MD
• Oral 9 Treatment of Alcohol Use Disorder in Patients Admitted with Alcohol-Associated Liver Disease: A Retrospective Cohort Study; Patrick Twohig, MD, MPH
• Oral 10 Machine Learning for Classification of Indeterminate Biliary Strictures During Cholangioscopy; Bachir Ghandour, MD
• Oral 18 Effect of Weight Loss Surgery and Weight Loss Medications on the Risk of Colorectal Cancer: A Nationwide Population-Based Cohort Study; Zryan Shwani, MD
• Oral 25 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial; Jessica R. Allegretti, MD, MPH, FACG
• Oral 35 Alcohol-Related Liver Disease Increased in Severity During the COVID-19 Pandemic; Lindsay A. Sobotka, DO
• Oral 43 Development and Validation of a Novel Scoring System for Bloating and Distension: The Mayo Bloating Questionnaire; David J. Cangemi, MD
• Oral 65 Comparative Safety of Biologic Agents in Patients with Inflammatory Bowel Disease with Active or Recent Malignancy: A Multi-Center Cohort Study; Ariela K. Holmer, MD
• Oral 69 Racial Minorities With Inflammatory Bowel Disease Are Under-Represented in Clinical Trial Participation; Jellyana Peraza, MD
• P0009 Concerning Trend in Increasing Pancreatic Cancer Incidence Among Young Women: A Population-Based Time-Trend Analysis Using the Surveillance, Epidemiology, and End Results (SEER) Database; Srinivas Gaddam, MD, MPH
• P0262 Fecal Microbiome Associated With Both Colon Adenomas and Lifetime Colorectal Cancer Risk; Sarah A. Alharfi, MD
• P0452 Selective Serotonin Reuptake Inhibitors Increase Risk of Upper Gastrointestinal Bleeding When Used with NSAIDs: A Systemic Review and Meta-Analysis; Syed Mobashshir Alam, MD
• P0897 Patient Perception of Telehealth Services Compared to In-Person Office Visits Across Multiple Gastroenterology Practices; Naresh Gunaratnam, MD
• P1196 Impact of Addition of 45-49-Year-Olds to Screening Colonoscopy on Overall Adenoma Detection Rates Using the GIQuIC Registry; Aasma Shaukat, MD, MPH, FACG
• P1457 Disparities in Emergency Department Wait Times for Acute Gastrointestinal Bleeding: Results From the National Hospital Ambulatory Medical Care Survey, 2009-2018; Mohamad Aghaie Meybodi, MD
• P2613 Safety of Ustekinumab in Older IBD Patients (≥60 Years): Pooled Safety Analysis Through 5 Years in CD and 2 Years in UC and All Approved Indications; Maria T. Abreu, MD
• P2639 Sexual Dysfunction Improves with Biologic Therapy in Men and Women with IBD; Gabriel Castillo, MD